Lifecare’s Chief Scientific Officer Steps Down as Company Enters Market-Focused Phase

Lifecare AS ( (DE:LFC0) ) just unveiled an announcement.

Lifecare ASA announced that Prof. Dr. Dr. med. Andreas Pfützner is stepping down as Chief Scientific Officer after more than nine years as a key contributor to the company’s implantable continuous glucose monitoring technology. The company credited him with helping advance its scientific foundation and move its CGM platform from concept to its current stage of development.

Although he is leaving his executive role, Prof. Pfützner will continue supporting Lifecare in an operational and advisory capacity, allowing the company to retain his scientific expertise and market insights. As Lifecare shifts its priorities toward product development, industrialization and preparation for market entry, it will initiate a process to secure continued leadership of its scientific activities, underscoring an important transition phase for the company and its stakeholders.

More about Lifecare AS

Lifecare ASA is a Norwegian MedTech and medical sensor company focused on developing next-generation implantable continuous glucose monitoring systems. The company leverages osmotic pressure as a sensing principle, aiming to enable precise monitoring of various analytes and molecules in humans and pets, with a particular emphasis on diabetes technology and glucose measurement solutions.

Lifecare’s technology platform targets the growing market for advanced diabetes management tools by offering implantable CGM devices designed for continuous, minimally invasive monitoring. Its sensor technology is positioned to support both medical and veterinary applications, potentially broadening its addressable market and strengthening its role in the wider biosensor and digital health ecosystem.

Average Trading Volume: 3,951,568

Current Market Cap: NOK114.6M

See more insights into LFC0 stock on TipRanks’ Stock Analysis page.